Neddylation is crucial for the degradation of certain proteins. However its role in regulating T cells is unknown. Neddylation is mediated by cullin-RING ligase (CRL) protein complex, an E3 ubiquitin ligase and its critical adapter element, SAG protein (sensitive to apoptosis gene protein). We explored the role of SAG and thus neddylation in T cells by utilizing two different, but complementary approaches, namely, genetic knock-out and chemical inhibition with small molecule. The T cell specific SAG KO animals were generated by crossing B6 SAG fl/fl mice with B6 LCK-Cre mice. The KO animals were viable. The splenic and thymic analyses showed no significant differences in the numbers of conventional T cells (Tcons) and Tregs between the KO and WT animals. In vitro functional analysis of Tcons, however, revealed that stimulation with either allogeneic splenocytes or by a-CD3 and a-CD28 antibody, SAG -/-T cells showed
significantly decreased proliferation (P<0.002). Phenotypic analysis following stimulation demonstrated that SAG -/-T cells showed reduced expression of CD69, CD44 and greater expression of CD62L when compared to WT-T cells (P<0.04). The KO-T cells also demonstrated reduced expression of T effector signature cytokines, IL-17, IFN-g and IL-4. Similar reduction in proliferation, activation marker expression and release of cytokines was observed when the WT-T cells were treated with small molecule inhibitor of neddylation, MLN4924. We next determined the in vivo relevance of SAG and neddylation in Tcons by utilizing the MHC disparate (B6/BALB/c) model of allogeneic BMT. The BALB/c animals were lethally irradiated and transplanted with TCD BM from either syngeneic or allogeneic WT-B6 animals along with 5x10 5 splenic T cells from either the WT B6 or SAG -/-B6 animals. The allogeneic animals that received SAG -/-T cells demonstrated markedly reduced clinical GVHD and significantly increased survival when compared to those that received WT-B6 T cells (P<0.001). Similar results were observed in B6/B6D2F1 model. To further confirm our results and to determine potential translational application, we utilized the small molecule MLN4924, once again in the B6/BALB/c system. The recipient mice were lethally irradiated and received 5 doses of MLN4924 (20mg/kg, day-1 to day +3 of BMT) along with WT-B6 T cells. Mice receiving MLN4924 demonstrated significantly decreased clinical GVHD and improved survival. Our studies thus demonstrate that SAG is a novel molecular target for regulating T cell responses and mitigating GVHD. Furthermore, the clinical availability of the small molecule, MLN4924, suggests that this strategy could be tested in carefully designed human clinical trial for attenuating GVHD. Background: Transplant of male recipients from female donors (F>M HCT) is well known as a risk factor for developing chronic graft-versus-host disease (cGVHD). We have so far suggested that B cell response against minor histocompatibility antigens encoded on the Y chromosome, called H-Y antigens, develops following F>M HCT and associates with cGVHD. Here, we hypothesize that pre-sensitization to HYantigen in a female donor may affect the post-HCT HY-IgG development and clinical outcomes following F>M HCT. This study uses our novel HY microarray to determine the prevalence and impact of donor HY-IgG. Methods: We measured IgG against 5 HY antigens (DBY, UTY, ZFY, EIF1AY, & RBS4Y) in 289 female donors (age:18-60) of high resolution 8/8 HLA-matched HCT facilitated by the NMDP between 1990-2002 and assessed the impact of HY seropositivity on cumulative cGVHD incidence and other clinical outcomes.
In addition, we studied 90 Stanford adult female donors and their corresponding male recipients between 2005 and 2012 who survived without relapse for at least 3m post-HCT and assessed the association of HY-IgG development between pre-and post-HCT. The cut-off value for seropositivity was defined as Q3 + 2xIQR, determined from plasma of 60 maledonors. HY-score was defined as the cumulative number of targeted HY antigens. (Table 3) . Conclusion: Half of female donors were HY-seropositive, but there were no enough evidence to suggest that the HY sensitization can predict clinical outcome. In fact, we provided little evidence of adoptive HY B-cell immunity transfer. On-going studies will relate female HY sensitization to parity and age. The absence of adoptive immune transfer might raise a concern for the efficacy of donor vaccination strategies to augment GVL benefit. The immunosuppressive function of IL10 producing regulatory B cells (Bregs) has been shown in several murine models of inflammation and autoimmune disease. However, there is a paucity of data regarding the existence of an equivalent regulatory B cell subset in humans and their relevance in the pathogenesis of chronic graft-versus-host disease (cGVHD) remains unknown. Here, we explored the regulatory properties of peripheral blood (PB)-derived human B cell subsets and their role in cGVHD. Using intracellular cytokine staining following in vitro stimulation with CD40 ligand, we showed that the majority of IL-10 producing B cells in healthy donors are found within the CD24 hi CD38 hi transitional and CD19 + IgM + CD27 + memory B cell subsets. Sortpurified IgM memory and transitional B cells suppressed the proliferation, as well as the release of IFN-g by CD3/CD28 stimulated CD4 + T cells. The inhibitory effect of IgM memory and transitional B cells on CD4 + T cell proliferation was cell dose dependent with the highest suppression was observed at a ratio of 1:1. These data suggest that human PB transitional and IgM memory B cells are endowed with suppressive function. This suppression was mediated partially via the provision of IL-10, but not TGF-ß, which we assessed by antibody blockade experiments. Additionally, the suppressive capacity of the B cell subsets was reversed by the addition of CD80 and CD86 mAbs. Using transwell experiments, we further determined that the suppressive function of Bregs is also partly dependent on direct T cell/B cell contact. Although blockade of IL-10 and IL-10R, CD80 and CD86 and separation of B cells and T cells by a transwell membrane individually did not completely reverse the suppressive ability of transitional and IgM memory B cells, a combination of these factors sufficiently reversed the ability of Breg subsets to suppress CD4+ T cell proliferation. Thus, analogous to murine experimental models the suppressive effect of human Breg cells involves both the release of IL-10 and co-receptor interaction. Additionally, Breg cells isolated from patients with cGVHD were refractory to CD40 stimulation and produced less IL-10 when compared to patients without cGVHD post-SCT and healthy controls. Likewise, the absolute number of IL-10 producing B cells was significantly lower in cGvHD patients compared to patients without cGVHD and healthy controls (p¼0.007), supporting the existence of both a qualitative and quantitative defect in IL-10 producing B cells in cGvHD. Our combined studies provide important new data defining the phenotype of B cell populations enriched in regulatory B cells in healthy humans and provide evidence of altered cellular function within such cells that may impact a broad range of deficiencies in immune regulatory cell function in cGvHD post transplant patients. Background: Commensal gut microbiota have been implicated in initiating and perpetuating intestinal graft versus host disease (iGVHD), but its role remains controversial. Recent murine studies have shown that iGVHD results in destruction of intestinal mucosal immune defenses resulting in expansion of pro-inflammatory bacteria (Enterobacteriaceae, ENTERO), and by prophylactically treating mice with oral antibiotics that suppress growth of ENTERO, iGVHD was significantly improved 1 . Furthermore, small-chain fatty acid producing (SCFA) Clostridia have been shown to induce colonic Treg cells, to dampen gut inflammation, and to cure IBD in mice 2 . But these findings have not been observed or replicated in humans. Methods: Stool samples were collected on a weekly basis from pediatric allogeneic BMT patients from 7/26/11 e 9/30/ 13. Bacterial and fungal gDNA was isolated from fecal specimens. Amplicons for 16S rRNA V4 variable region and fungal ITS region were generated and sequenced on Roche 454 GS-FLX sequencer and Illumina HiSeq2000 respectively. Sequencing data was analyzed using QIIME software. The abundance of specific intestinal bacterial groups was determined by qPCR using group-specific 16S rRNA gene primers. For patients undergoing intestinal biopsy for suspicion of iGVHD (abdominal pain, diarrhea), additional pieces of intestine were obtained for transcription profiling experiments using Illumina Human HT12 V4 Expression BeadChips. Clinical characteristics (i.e. conditioning regimens, specific antibiotic use, immunosuppression, etc) were recorded. +  3 2  1 3   27  19   31  0   33  0   38  3 
